Biomarker-Guided Therapies in Heart Failure: A Forum for Unified Strategies

被引：12

作者：

Fiuzat, Mona ^{[1
]}

O'Connor, Christopher M. ^{[1
]}

Gueyffier, Francois ^{[2
,3
]}

Mascette, Alice M. ^{[4
]}

Geller, Nancy L. ^{[4
]}

Mebazaa, Alexandre ^{[5
]}

Voors, Adriaan A. ^{[6
]}

Adams, Kirkwood F. ^{[7
]}

Pina, Ileana L. ^{[8
]}

Neyses, Ludwig ^{[9
]}

Muntendam, Pieter ^{[10
]}

Felker, G. Michael ^{[1
]}

Pitt, Bertram ^{[11
]}

Zannad, Faiez ^{[12
]}

Bristow, Michael R. ^{[13
,14
]}

机构：

[1] Duke Univ Med Ctr, Durham, NC USA

[2] Hosp Civils Lyon, Lyon, France

[3] Univ Lyon 1, UMR5558, CNRS, F-69365 Lyon, France

[4] NHLBI, Bethesda, MD 20892 USA

[5] Lariboisiere Hosp, Paris, France

[6] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands

[7] Univ N Carolina, Chapel Hill, NC USA

[8] Montefiore Einstein Med Ctr, New York, NY USA

[9] Univ Manchester, Manchester, Lancs, England

[10] BG Med, Waltham, MA USA

[11] Univ Michigan, Ann Arbor, MI 48109 USA

[12] Nancy Univ, Nancy, France

[13] Univ Colorado Hlth Sci Ctr, Denver, CO USA

[14] ARCA Biopharma, Denver, CO USA

来源：

JOURNAL OF CARDIAC FAILURE | 2013年 / 19卷 / 08期

基金：

美国国家卫生研究院;

关键词：

Pharmacogenetics; biologic markers; clinical trials; cardiovascular diseases; BRAIN-NATRIURETIC PEPTIDE; ROSUVASTATIN MULTINATIONAL TRIAL; ADRENERGIC-RECEPTOR GENOTYPES; CARDIOVASCULAR-DISEASE; DIAGNOSTIC BIOMARKERS; POLYMORPHISM; ASSOCIATION; GENE; MANAGEMENT; UTILITY;

D O I：

10.1016/j.cardfail.2013.05.012

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The complexity of standard medical treatment for heart failure is growing, and such therapy typically involves 5 or more different medications. Given these pressures, there is increasing interest in harnessing cardiovascular biomarkers for clinical application to more effectively guide diagnosis, risk stratification, and therapy. It may be possible to realize an era of personalized medicine for heart failure treatment in which therapy is optimized and costs are controlled. The direct mechanistic coupling of biologic processes and therapies achieved in cancer treatment remains elusive in heart failure. Recent clinical trials and meta-analyses of biomarkers in heart failure have produced conflicting evidence. In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union.

引用

页码：592 / 599

页数：8

共 75 条

[1] Novel biomarkers in chronic heart failure [J].